Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-2 study of bb2121 in relapsed/refractory or high-risk multiple myeloma
2018-000264-28Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Started Aug 2018; status: recruiting.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-000264-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000264-28.